In the Early Treatment Diabetic Retinopathy Study (ETDRS), clinically significant macular edema is defined by which criterion?

Explanation

## ETDRS Criteria for Clinically Significant Macular Edema (CSME) **Key Point:** The ETDRS established three specific criteria for defining clinically significant macular edema (CSME). At least ONE of the following must be present: ### ETDRS Definition of CSME (Any ONE of the following) | Criterion | Measurement | |-----------|-------------| | **Retinal thickening** | Within 500 micrometers of the foveal center | | **Hard exudates** | Within 500 micrometers of the foveal center **with adjacent retinal thickening** | | **Retinal thickening** | ≥1 disc area in size, any part of which is within 1 disc diameter of the foveal center | **High-Yield:** The classic ETDRS CSME criteria do NOT use a "250 µm within 1500 µm" threshold — that is a common distractor. The correct criteria involve: 1. Retinal thickening **at or within 500 µm** of the foveal center 2. Hard exudates **at or within 500 µm** of the foveal center with adjacent thickening 3. Retinal thickening **≥1 disc area** within 1 disc diameter of the fovea **Why Option D is correct:** Hard exudates within 500 micrometers of the foveal center (with associated retinal thickening) is one of the three canonical ETDRS CSME criteria, as defined in the original ETDRS Report Number 1 (Ophthalmology, 1985). Among the options provided, this is the only one that accurately reflects a true ETDRS criterion without distortion. **Why Options B and C are incorrect:** The "≥250 µm within 1500 µm" and "≥500 µm within 500 µm" thresholds are not the standard ETDRS CSME definitions as published. The ETDRS criteria are based on proximity to the fovea (within 500 µm or within 1 disc diameter) and disc-area size, not on specific micrometer thickness thresholds (which are OCT-era constructs). ### Clinical Significance - **CSME indicates:** Significant risk of vision loss if untreated - **Treatment threshold:** Presence of CSME warrants intervention (focal/grid laser or anti-VEGF agents) - **Prognosis:** Without treatment, ~50% of eyes with CSME develop moderate vision loss within 3 years (ETDRS Report) **Clinical Pearl:** The ETDRS criteria were developed in the pre-OCT era using slit-lamp biomicroscopy and stereoscopic fundus photography. Modern OCT provides precise quantification of macular thickness but the original ETDRS definitions remain the gold standard for clinical classification. *Reference: Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS Report Number 1. Arch Ophthalmol. 1985;103(12):1796–1806.*